Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
1(33%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_4
1
33%
Ph not_applicable
1
33%
Ph phase_2
1
33%

Phase Distribution

0

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution3 total trials
Phase 2Efficacy & side effects
1(33.3%)
Phase 4Post-market surveillance
1(33.3%)
N/ANon-phased studies
1(33.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

3

all time

Status Distribution
Active(2)
Completed(1)

Detailed Status

Recruiting1
Completed1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
1
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 21 (33.3%)
Phase 41 (33.3%)
N/A1 (33.3%)

Trials by Status

recruiting133%
completed133%
not_yet_recruiting133%

Recent Activity

1 active trials
Showing 3 of 3
not_yet_recruitingphase_4

The Value of Adding Mini-oral Pulse Steroid Therapy in Preventing Peri-lesional Halo Post Non-cultured Epidermal Cell Suspension (NCES) in Cases With Stable Segmental and Non-acral Vitiligo.

NCT07472816
completednot_applicable

T Central Memory Cells in Early Localized Non-Segmental Vitiligo

NCT05706636
recruitingphase_2

Vitiligo, New Treatment and Serum s100B

NCT06768840

Clinical Trials (3)

Showing 3 of 3 trials
NCT07472816Phase 4

The Value of Adding Mini-oral Pulse Steroid Therapy in Preventing Peri-lesional Halo Post Non-cultured Epidermal Cell Suspension (NCES) in Cases With Stable Segmental and Non-acral Vitiligo.

Not Yet Recruiting
NCT05706636Not Applicable

T Central Memory Cells in Early Localized Non-Segmental Vitiligo

Completed
NCT06768840Phase 2

Vitiligo, New Treatment and Serum s100B

Recruiting

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3